NOVEL PEPTIDES AND COMBINATION OF PEPTIDES FOR USE IN IMMUNOTHERAPY AGAINST LUNG CANCER, INCLUDING NSCLC, SCLC AND OTHER CANCERS
The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumor-associated T-cell peptide epitopes, alone or in combination with other tumor-associated peptides that can for example serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses, or to stimulate T cells ex vivo and transfer into patients. Peptides bound to molecules of the major histocompatibility complex (MHC), or peptides as such, can also be targets of antibodies, soluble T-cell receptors, and other binding molecules.
1 . A peptide consisting of the amino acid sequence SARLATDAL (SEQ ID NO: 241) in the form of a pharmaceutically acceptable salt.
2 . The peptide of claim 1 , wherein said peptide has the ability to bind to an MHC class-I molecule, and wherein said peptide, when bound to said MHC, is capable of being recognized by CD8 T cells.
3 . The peptide of claim 1 , wherein the pharmaceutically acceptable salt is chloride salt.
4 . The peptide of claim 1 , wherein the pharmaceutically acceptable salt is acetate salt.
5 . A composition comprising the peptide of claim 1 , wherein the composition comprises an adjuvant and a pharmaceutically acceptable carrier.
6 . The composition of claim 5 , wherein the peptide is in the form of a chloride salt.
7 . The composition of claim 5 , wherein the peptide is in the form of an acetate salt.
8 . The composition of claim 5 wherein the adjuvant is selected from the group consisting of anti-CD40 antibody, imiquimod, resiquimod, GM-CSF, cyclophosphamide, sunitinib, bevacizumab, interferon-alpha, interferon-beta, CpG oligonucleotides and derivatives, poly-(I:C) and derivatives, RNA, sildenafil, particulate formulations with poly(lactide co-glycolide) (PLG), virosomes, interleukin (IL)-1, IL-2, IL-4, IL-7, IL-12, IL-13, IL-15, IL-21, and IL-23.
9 . The composition of claim 8 , wherein the adjuvant is IL-2.
10 . The composition of claim 8 , wherein the adjuvant is IL-7.
11 . The composition of claim 8 , wherein the adjuvant is IL-12.
12 . The composition of claim 8 , wherein the adjuvant is IL-15.
13 . The composition of claim 8 , wherein the adjuvant is IL-21.
14 . A pegylated peptide consisting of the amino acid sequence of SARLATDAL (SEQ ID NO: 241) or a pharmaceutically acceptable salt thereof.
15 . The peptide of claim 14 , wherein the pharmaceutically acceptable salt is chloride salt.
16 . The peptide of claim 14 , wherein the pharmaceutically acceptable salt is acetate salt.
17 . A composition comprising the pegylated peptide of claim 14 or pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier.
18 . The composition of claim 5 , wherein the pharmaceutically acceptable carrier is selected from the group consisting of saline, Ringer's solution, dextrose solution, and sustained release preparation.
19 . The peptide in the form of a pharmaceutically acceptable salt of claim 1 , wherein said peptide is produced by solid phase peptide synthesis or produced by a yeast cell or bacterial cell expression system.
20 . A composition comprising the peptide of claim 1 , wherein the composition is a pharmaceutical composition and comprises water and a buffer.